SLC7A5 and uterine cancer: Finally, the positive rates of LAT1 were 100% for oral cancer, 90% for pharyngeal cancer, 94% for esophageal cancer, 100% for lung squamous cell carcinoma, 80% for gastric cancer, 100% for colorectal cancer, 67% for ovarian cancer, 100% for uterine cancer, 100% for germ cell tumor, 55% for melanoma, 50% for biliary tract cancer, 49% for lung adenocarcinoma, 42% for breast cancer, 38% for neuroblastoma, 31% for pancreatic cancer, and 30% for nephroblastoma.